12 Health Care Stocks Moving In Tuesday's After-Market Session
Verrica Pharmaceuticals Inc VRCA
$5.22
▼ -0.76%
($-0.04)
🎈 Low Float
📅 Earnings This Week
Open
$5.27
Prev Close
$5.26
Day Range
$5.21 – $5.55
52W Range
$3.28 – $9.82
Market Cap
$91.22M
Beta
1.51
EPS (TTM)
$-1.03
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-06-15 |
| Shares Out. | 17,180,000 |
| Website | verrica.com/ ↗ |
| Phone | 13026365400 |
| Employees | 76 |
| Revenue | $5.0M |
| Gross Profit | $4.1M |
| Net Income | -$9.7M |
| Total Assets | $38.8M |
| Total Liabilities | $22.7M |
| Equity | $16.1M |
About Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Verrica Pharmaceuticals Inc is a publicly traded company under the ticker symbol VRCA on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)
📰 Latest News for VRCA
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
Verrica Pharmaceuticals Grants Medomie Pharma Rights To Seek Israeli Regulatory Approval For And To Distribute YCANTH For The Treatment Of Molluscum Contagiosum With Up To $8.2M In Milestones